A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

NCT02981446 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma or Ocular Hypertension

Interventions

DRUG: DE-117
DRUG: Latanoprost ophthalmic solution

Sponsor

Santen Pharmaceutical Co., Ltd.